Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (18)

2024

  1. Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis

    Journal of Infection and Public Health, Vol. 17, Núm. 10

  2. Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy

    Frontiers in Cellular and Infection Microbiology, Vol. 14

2023

  1. Corrigendum to “PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study” [Biomed. Pharmacother. 159 (2023) 114220] (Biomedicine & Pharmacotherapy (2023) 159, (S0753332223000082), (10.1016/j.biopha.2023.114220))

    Biomedicine and Pharmacotherapy

  2. MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected

    Journal of Molecular Medicine, Vol. 101, Núm. 11, pp. 1409-1420

  3. PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study

    Biomedicine and Pharmacotherapy, Vol. 159

  4. Predictive plasma biomarkers of long-term increase in hepatic steatosis index after HCV eradication in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 3, pp. 719-726

  2. Dynamics of HIV Reservoir and HIV‐1 Viral Splicing in HCV‐Exposed Individuals after Elimination with DAAs or Spontaneous Clearance

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  3. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 147

  4. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients

    Frontiers in Immunology, Vol. 12

  2. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

2020

  1. Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case-control study

    AIDS (London, England), Vol. 34, Núm. 13, pp. 1891-1897

  2. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  3. Telomere length increase in HIV/HCV-coinfected patients with cirrhosis after HCV eradication with direct-acting antivirals

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-13

2016

  1. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1

  2. Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfected patients on Hepatitis C Virus therapy

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 3, pp. 226-231

2013

  1. Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 63, Núm. 2, pp. 178-183